ArticleNature materials2024
An intelligent DNA nanodevice for precision thrombolysis.
Article in Nature materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- DNA nanodevice-engineered macrophages as living sensors for dual-mode in vivo monitoring of tumor-associated macrophage polarization.Science advances · 2026Article
- Efficient fluorescence strategy based on a DNA tetrahedral nanodevice for intracellular hypochlorous acid imaging.Mikrochimica acta · 2026Article
- A Cascaded DNA Nanocircuit for Multi-Signal-Responsive Precision siRNA Delivery in Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable DNA Logic Systems for Applications in Biomedicine.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Spatially Encoded Protocell Network for Non-Cascaded Parallel Biocomputation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Geometry-Programmable Living Immunomaterials for Spatial Control of Innate Immune Signaling.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Transforming stroke care: the promise of feedback-guided thrombolytic nanomedicine.Journal of nanobiotechnology · 2026Review
- Prospects of DNA nanotechnology in stroke repair and regeneration.Communications biology · 2026Review
- Multivalent Aptamers: Contemporary Engineering Strategies and Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Tumor microenvironment responsive nano-immunoregulator for precision cancer photodynamic immunotherapy.Materials today. Bio · 2026Article
- Dynamic DNA Nanomachines for Biosensing and Drug Delivery.Sensors (Basel, Switzerland) · 2026Review
- A DNA Origami-Based Cobweb Facilitates Precise and Receptor-Interference Free Modification of Extracellular Vesicle Mimetic for Enhanced Delivery Efficacy.Journal of the American Chemical Society · 2026Article
- A pH-stable dynamic DNA nanomachine with controllable conformational switching.Nanoscale advances · 2026Article
- Synthetic aptamer mechanoreceptors enable cell-specific force sensing and temporal control via DNA circuits.Nature communications · 2026Article
- Thrombolytic therapy in vertebrobasilar dolichoectasia patients with acute posterior circulation cerebral infarction: a case series analysis.Thrombosis journal · 2026Article
- Recent Advances in Aptamer-Based Applications in Cardiology.International journal of molecular sciences · 2026Review
- Engineering a Mechanoresponsive DNA Origami Capsule for Drug Delivery to Narrowed Arteries.Nano letters · 2026Article
- In situ coagulation environment regulation-assisted thrombus clearance via hydrogenated silicon-based nanothrombolytics.Science advances · 2026Article
- A DNA-based nanodevice senses purinergic signaling and drives an immune switch for resolving inflammation.Nature communications · 2026Article
- Cocklebur-inspired magnetic nanomotors for targeted thrombus therapy.Bioactive materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Thrombosis is a leading global cause of death, in part due to the low efficacy of thrombolytic therapy. Here, we describe a method for precise delivery and accurate dosing of tissue plasminogen activator (tPA) using an intelligent DNA nanodevice. We use DNA origami to integrate DNA nanosheets with predesigned tPA binding sites and thrombin-responsive DNA fasteners. The fastener is an interlocking DNA triplex structure that acts as a thrombin recognizer, threshold controller and opening switch. When loaded with tPA and intravenously administrated in vivo, these DNA nanodevices rapidly target the site of thrombosis, track the circulating microemboli and expose the active tPA only when the concentration of thrombin exceeds a threshold. We demonstrate their improved therapeutic efficacy in ischaemic stroke and pulmonary embolism models, supporting the potential of these nanodevices to provide accurate tPA dosing for the treatment of different thromboses.
Indexed as
Identifiers
38448659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.